James Luke Godwin Shuchie Jaggi Imali Sirisena Pankaj Sharda Ajay D Rao Ranee Mehra Colleen Veloski
10.1186/s40425-017-0245-2
J Immunother Cancer
2017 May 16;5:40.
autoimmune diabetes diabetic ketoacidosis (dka) immune related adverse events (irae) nivolumab non-small cell lung cancer (nsclc) pd-1 inhibitor
CC BY
https://pubmed.ncbi.nlm.nih.gov/28515940/
Adenocarcinoma / secondary Antibodies, Monoclonal / adverse effects Antineoplastic Agents / adverse effects Diabetes Mellitus, Type 1 / chemically induced Diabetic Ketoacidosis / chemically induced Lung Neoplasms / drug therapy
Adenocarcinoma / secondary Antibodies, Monoclonal / adverse effects Antineoplastic Agents / adverse effects Diabetes Mellitus, Type 1 / chemically induced Diabetic Ketoacidosis / chemically induced Lung Neoplasms / drug therapy Case Reports Adenocarcinoma / drug therapy Adult Female Humans Nivolumab Programmed Cell Death 1 Receptor / antagonists & inhibitors Antibodies, Monoclonal Antineoplastic Agents PDCD1 protein, human Programmed Cell Death 1 Receptor Nivolumab
PMC5433051
28515940
Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
2017